Raul Ayala

1.1k total citations
18 papers, 830 citations indexed

About

Raul Ayala is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Raul Ayala has authored 18 papers receiving a total of 830 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in Raul Ayala's work include Advanced Breast Cancer Therapies (5 papers), HER2/EGFR in Cancer Research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Raul Ayala is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), HER2/EGFR in Cancer Research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Raul Ayala collaborates with scholars based in United States, Australia and Portugal. Raul Ayala's co-authors include Dennis J. Slamon, Beth Y. Karlan, Mark R. Bray, Bryan E. Snow, John F. Lyons, Fairooz F. Kabbinavar, Richard S. Finn, Zev A. Wainberg, Tong Luo and Amrita Desai and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Clinical Cancer Research.

In The Last Decade

Raul Ayala

17 papers receiving 813 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raul Ayala United States 9 483 356 253 124 84 18 830
Emmy D.G. Fleuren Netherlands 17 497 1.0× 368 1.0× 307 1.2× 108 0.9× 56 0.7× 25 871
Smruthi Vijayaraghavan United States 10 412 0.9× 571 1.6× 352 1.4× 126 1.0× 68 0.8× 15 914
Rosalin Mishra United States 11 421 0.9× 345 1.0× 139 0.5× 81 0.7× 131 1.6× 20 724
Cansu Karakaş United States 18 433 0.9× 608 1.7× 374 1.5× 213 1.7× 85 1.0× 36 1.0k
Yongmei Yin China 13 396 0.8× 321 0.9× 189 0.7× 164 1.3× 69 0.8× 41 733
Lisa Malburg United States 9 493 1.0× 405 1.1× 181 0.7× 99 0.8× 76 0.9× 14 780
Jean Powers Canada 9 420 0.9× 330 0.9× 265 1.0× 209 1.7× 56 0.7× 12 748
Loredana Militello Italy 9 355 0.7× 319 0.9× 197 0.8× 205 1.7× 52 0.6× 19 746
Kelly Waldeck Australia 13 350 0.7× 361 1.0× 201 0.8× 123 1.0× 150 1.8× 24 784
Michel Maira Switzerland 8 629 1.3× 269 0.8× 180 0.7× 129 1.0× 56 0.7× 12 837

Countries citing papers authored by Raul Ayala

Since Specialization
Citations

This map shows the geographic impact of Raul Ayala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raul Ayala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raul Ayala more than expected).

Fields of papers citing papers by Raul Ayala

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raul Ayala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raul Ayala. The network helps show where Raul Ayala may publish in the future.

Co-authorship network of co-authors of Raul Ayala

This figure shows the co-authorship network connecting the top 25 collaborators of Raul Ayala. A scholar is included among the top collaborators of Raul Ayala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raul Ayala. Raul Ayala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
O’Brien, Neil A., Martina S.J. McDermott, KeWei Gong, et al.. (2023). Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers. Molecular Cancer Therapeutics. 22(12). 1365–1375. 5 indexed citations
2.
Tejeda‐Muñoz, Nydia, et al.. (2023). The PMA phorbol ester tumor promoter increases canonical Wnt signaling via macropinocytosis. eLife. 12. 8 indexed citations
3.
Roy, Sasmit, Jean Hou, Prabal Chourasia, et al.. (2023). Seronegative Atypical Anti-Glomerular Basement Membrane Glomerulonephritis Associated With Thrombotic Microangiopathy: Case Report and Literature Analysis. Journal of Investigative Medicine High Impact Case Reports. 11. 1626032504–1626032504.
4.
Roy, Sasmit, et al.. (2022). Acute Interstitial Nephritis Induced by Clozapine. Journal of Medical Cases. 13(7). 322–329. 2 indexed citations
5.
Suh, Eul Hyun, Carlos F. G. C. Geraldes, Sara Chirayil, et al.. (2021). Detection of glucose-derived d- and l-lactate in cancer cells by the use of a chiral NMR shift reagent. SHILAP Revista de lepidopterología. 9(1). 38–38. 12 indexed citations
6.
Roy, Sasmit, et al.. (2021). Neisseria cinerea-Mediated Peritonitis in an End-Stage Renal Disease Patient on Continuous Ambulatory Peritoneal Dialysis. Cureus. 13(12). e20661–e20661. 3 indexed citations
7.
Roy, Sasmit, et al.. (2021). Severe Hypertriglyceridaemia Leading to Factitious Hypobicarbonataemia. SHILAP Revista de lepidopterología. 8(12). 3046–3046. 2 indexed citations
8.
O’Brien, Neil A., Martina S.J. McDermott, Dylan Conklin, et al.. (2020). Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Research. 22(1). 89–89. 87 indexed citations
9.
O’Brien, Neil A., Dylan Conklin, Alex Gaither, et al.. (2019). Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models. 3825–3825. 1 indexed citations
10.
O’Brien, Neil A., Martina S.J. McDermott, Dylan Conklin, et al.. (2019). Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models. Cancer Research. 79(13_Supplement). 3825–3825. 1 indexed citations
11.
Conklin, Douglas S., Michael McDermott, Tong Luo, et al.. (2019). Abstract P6-17-11: The small molecule inhibitor of HER2, tucatinib, has potent and highly selective activity in preclinical modes of HER2-driven cancer. Cancer Research. 79(4_Supplement). P6–17. 5 indexed citations
12.
O’Brien, Neil A., Dylan Conklin, Tong Luo, et al.. (2017). Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy. Cancer Research. 77(13_Supplement). 4150–4150. 4 indexed citations
13.
O’Brien, Neil A., Emmanuelle di Tomaso, Raul Ayala, et al.. (2014). Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer. Cancer Research. 74(19_Supplement). 4756–4756. 38 indexed citations
14.
Wainberg, Zev A., Adrian Anghel, Amrita Desai, et al.. (2013). Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer. Molecular Cancer Therapeutics. 12(4). 509–519. 58 indexed citations
15.
Konecny, Gottfried E., Teodora Kolarova, Neil A. O’Brien, et al.. (2013). Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells. Molecular Cancer Therapeutics. 12(5). 632–642. 68 indexed citations
16.
Wainberg, Zev A., Adrian Anghel, Amrita Desai, et al.. (2010). Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo. Clinical Cancer Research. 16(5). 1509–1519. 171 indexed citations
17.
Zhang, Liqun, Steven Wong, Raul Ayala, et al.. (2006). Imaging Mitogen-Activated Protein Kinase Function in Xenograft Models of Prostate Cancer. Cancer Research. 66(22). 10778–10785. 12 indexed citations
18.
Lyons, John F., Fairooz F. Kabbinavar, Mark R. Bray, et al.. (2003). Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.. PubMed. 63(1). 196–206. 353 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emmy D.G. Fleuren Breakdown of academic impact, for papers by Smruthi Vijayaraghavan Breakdown of academic impact, for papers by Rosalin Mishra Breakdown of academic impact, for papers by Cansu Karakaş Breakdown of academic impact, for papers by Yongmei Yin Breakdown of academic impact, for papers by Lisa Malburg Breakdown of academic impact, for papers by Jean Powers Breakdown of academic impact, for papers by Loredana Militello Breakdown of academic impact, for papers by Kelly Waldeck Breakdown of academic impact, for papers by Michel Maira
Rankless by CCL
2026